Emerging advanced therapies such as CAR-T and gene therapies have the potential to cure previously intractable conditions with a single infusion. Unfortunately, these incredible treatments remain out of the reach of many due to current vector technology limiting efficacy, quality, and manufacturing viability. 

Lentitek has a unique manufacturing technology that can significantly improve the production quality of the lentivirus vector used in advanced therapies and enable new applications such as in-vivo CAR-T and armoured CARs. Additionally, the improvement in manufacturing quality can lead to higher yields and improved product potency.

Providing patients with a new way to benefit from Naltrexone

We transform promising life science ideas into medical breakthroughs that change patients’ lives.

Making life science life changing: We transform promising life science ideas into medical breakthroughs that change patients’ lives.

We specialise in early-stage translation – advancing lab-based scientific discoveries to a point at which they can be developed into the next generation of diagnostics, treatments and cures.

Lifescience Industry magazine is a collaboration between regional, national and international life science partners including BioPartner UK.

It includes the latest news and developments from the life science industry, with editorial covering the complete health technology spectrum, as well as funding, trade and collaboration opportunities. 
Currently circulated twice a year to over 40,000 named individuals, it is consistently distributed at key industry events around the world and is available online.

BioPartner members can submit articles free of charge, and receive 15% off all advertising packages.